Lacidipine (International)
Scheme
Rec.INN
ATC (Anatomical Therapeutic Chemical Classification)
C08CA09
CAS registry number (Chemical Abstracts Service)
0103890-78-4
Chemical Formula
C26-H33-N-O6
Molecular Weight
346
Therapeutic Categories
Antihypertensive agent
Calcium channel blocker
Chemical Name
3,-5-Pyridinedicarboxilic acid,4-[2-[3-(1,1-dimetyletoxy)-3-oxo-1-propenyl]phenyl]-1,4-dihydro-2,6-dimetyl-,dietyl ester, (E)-
Foreign Names
- Lacidipinum (Latin)
- Lacidipin (German)
- Lacidipine (French)
- Lacidipino (Spanish)
Generic Names
- Lacidipina (OS: DCIT)
- Lacidipine (OS: USAN, DCF, BAN, JAN)
- GR 43659 X (Glaxo) (IS)
- GX 1048 (Glaxo) (IS)
- Lacidipine (PH: BP 2018)
Brand Names
- Aponil
Glaxo Allen, Italy - Lacibloc
Ultramed, Philippines - Lacicard
Aristopharma, Bangladesh - Lacidac
Delta Pharma, Egypt - Lacidipin Belupo
Belupo, Croatia (Hrvatska) - Lacidipin Double-E Pharma
Copharma, Denmark - Lacidipin Teva
Teva, Denmark; Teva, Lithuania - Lacidipina Rivopharm
Rivopharm, Italy - Lacidipine
Doc Generici, Malta; Dr. Reddy's, United Kingdom; Rivopharm UK, United Kingdom - Lacidipine Double-E Pharma
Alpha-Medical, Croatia (Hrvatska); Double-E Pharma, Lithuania; Double-E Pharma Limited, Netherlands - Lacidipine Teva
Teva Nederland, Netherlands; Teva Pharmaceuticals, Poland - Lacidipino Teva
Teva, Spain - Lacimen
GlaxoSmithKline, Spain - Lacipil
Glaxo, Bulgaria; Glaxo Group, Romania; Glaxo Wellcome, Portugal; GlaxoSmithKline, Bulgaria; GlaxoSmithKline, Estonia; GlaxoSmithKline, Egypt; GlaxoSmithKline, Spain; GlaxoSmithKline, Georgia; GlaxoSmithKline, Hong Kong; GlaxoSmithKline, Croatia (Hrvatska); GlaxoSmithKline, Italy; GlaxoSmithKline, Lithuania; GlaxoSmithKline, Latvia; GlaxoSmithKline, Mexico; GlaxoSmithKline, Malaysia; GlaxoSmithKline, Philippines; GlaxoSmithKline, Poland; GlaxoSmithKline, Turkey; GlaxoSmithKline, Taiwan; GlaxoSmithKline, Venezuela; GlaxoSmithKline A.B.E.E., Greece; GlaxoSmithKline Brasil, Brazil; GSK, Czech Republic; GSK, Slovakia; Wellcome Limited, Bosnia & Herzegowina; GlaxoSmithKline China Investment, China - Lacipil 2 mg
GlaxoSmithKline, Hungary - Lacipil 4 mg
GlaxoSmithKline, Hungary - Lacirex
Laboratori Guidotti, Italy - Lacitens
GlaxoSmithKline A.B.E.E., Greece - Lacivas
Sun, India - Lacydyna
Alpha-Medical, Croatia (Hrvatska); Rivopharm, Poland - Ladip
Glaxo Allen, Italy - Lanidiem
Samil, South Korea - Lapixen
Biofarm, Poland - Lasyn
Synmosa, Taiwan - Lodipine
Egyphar, Egypt - Midotens
Boehringer Ingelheim, Mexico - Monopin
Pliva, Bosnia & Herzegowina; Pliva, Croatia (Hrvatska) - Motens
Boehringer Ingelheim, Greece; Boehringer Ingelheim España, Spain; GlaxoSmithKline UK, United Kingdom - Prelum
double-e pharma, Latvia - Sileping
Hayao Pharmaceutical Group Holding, China - Sinopil
GlaxoSmithKline, India - Viapres
Crinos, Italy
Glossary
| Term | Definition |
|---|---|
| BAN | British Approved Name |
| DCF | Dénomination Commune Française |
| DCIT | Denominazione Comune Italiana |
| IS | Inofficial Synonym |
| JAN | Japanese Accepted Name |
| OS | Official Synonym |
| PH | Pharmacopoeia Name |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
Further information on drug naming conventions: International Nonproprietary Names.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.